Inventor · disambiguated record
Timothy Heffernan
Also filed as: HEFFERNAN TIMOTHY · HEFFERNAN TIMOTHY P
16 granted patents·10 pending applications·92 citations·filing 2011–2024
93Inventor score
Top patents by PatentIndex Score
26 records- 0196US11370786B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Jun 28, 2022·6 cites·17 claims
- 0295US11958849B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2022·Granted Apr 16, 2024·2 cites·12 claims
- 0394US11045443B2Glutaminase inhibitor therapyUNIV TEXAS·Filed 2020·Granted Jun 29, 2021·7 cites·27 claims
- 0494US10766892B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2019·Granted Sep 8, 2020·9 cites·26 claims
- 0593US11713313B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2020·Granted Aug 1, 2023·3 cites·12 claims
- 0693US10722487B2Glutaminase inhibitor therapyUNIV TEXAS·Filed 2018·Granted Jul 28, 2020·9 cites·35 claims
- 0793US9809588B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Granted Nov 7, 2017·15 cites·27 claims
- 0892US10738043B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2018·Granted Aug 11, 2020·6 cites·12 claims
- 0992US10344025B2GLS1 inhibitors for treating diseaseUNIV TEXAS·Filed 2017·Granted Jul 9, 2019·12 cites·11 claims
- 1091US11786500B2Glutaminase inhibitor therapyUNIV TEXAS·Filed 2021·Granted Oct 17, 2023·2 cites·10 claims
- 1191US11311609B2Regulating chimeric antigen receptorsDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 26, 2022·6 cites·29 claims
- 1291US10125128B2GLS1 inhibitors for treating diseaseBOARD OF REGENTS UNIV OF TEXAS SYSTEM·Filed 2016·Granted Nov 13, 2018·13 cites·21 claims
- 1386US11046954B2Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2018·Granted Jun 29, 2021·2 cites·17 claims
- 1486US2024360121A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1584US12336976B2Glutaminase inhibitor therapyUNIV TEXAS·Filed 2023·Granted Jun 24, 2025·0 cites·14 claims
- 1674US2022135967A1Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 1771US2021301286A1Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responsesDANA FARBER CANCER INST INC·Filed 2021·Application pending·0 cites
- 1868US11293023B2Tunable endogenous protein degradationDANA FARBER CANCER INST INC·Filed 2018·Granted Apr 5, 2022·0 cites·13 claims
- 1960US2019134032A1Glutaminase inhibitor therapyUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2051US2016058759A1Glutaminase inhibitor therapyUNIV TEXAS·Filed 2015·Application pending·0 cites
- 2150US2014011748A1Methods Of Predicting Response To JNK Inhibitor TherapyCHIN LYNDA·Filed 2012·Application pending·0 cites
- 2248US12023385B2Tunable endogenous protein degradation with heterobifunctional compoundsDANA FARBER CANCER INST INC·Filed 2018·Granted Jul 2, 2024·0 cites·24 claims
- 2340US2016002204A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Application pending·0 cites
- 2439US2020164034A1Methods for improving sex-dimorphic responses to targeted therapy in melanomaUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2537US2013040853A1Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target ValidationDANA FARBER CANCER INST INC·Filed 2011·Application pending·0 cites
- 2635US2016002248A1Gls1 inhibitors for treating diseaseUNIV TEXAS·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Timothy Heffernan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →